OTCMKTS:ATBPF Antibe Therapeutics (ATBPF) Stock Price, News & Analysis $0.22 0.00 (0.00%) As of 04/3/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartShort InterestBuy This Stock About Antibe Therapeutics Stock (OTCMKTS:ATBPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Antibe Therapeutics alerts:Sign Up Key Stats Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.11▼$0.89VolumeN/AAverage Volume27,352 shsMarket Capitalization$11.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAntibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Read More… Remove Ads Receive ATBPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATBPF Stock News HeadlinesAPLIF Appili Therapeutics Inc.August 23, 2024 | seekingalpha.comANTIBE THERAPEUTICS INC (ATBPF) stock forecast and price targetJuly 19, 2024 | finance.yahoo.comFBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” by several years…April 4, 2025 | Colonial Metals (Ad)Antibe Announces Appointment of ReceiverApril 24, 2024 | finance.yahoo.comAntibe Announces Appointment of ReceiverApril 24, 2024 | businesswire.comAntibe Provides Update on CCAA ProceedingsApril 19, 2024 | businesswire.comAntibe Announces TSX Delisting ReviewApril 16, 2024 | finance.yahoo.comAntibe Announces Granting of Initial Order Under Companies' Creditors Arrangement ActApril 9, 2024 | businesswire.comSee More Headlines ATBPF Stock Analysis - Frequently Asked Questions How have ATBPF shares performed this year? Antibe Therapeutics' stock was trading at $0.2156 at the start of the year. Since then, ATBPF stock has increased by 0.0% and is now trading at $0.2156. View the best growth stocks for 2025 here. How were Antibe Therapeutics' earnings last quarter? Antibe Therapeutics Inc. (OTCMKTS:ATBPF) issued its quarterly earnings data on Monday, November, 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. How do I buy shares of Antibe Therapeutics? Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/13/2023Today4/04/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ATBPF CIKN/A Webwww.antibethera.com Phone(416) 922-3460FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.48% Return on Assets-29.07% Debt Debt-to-Equity RatioN/A Current Ratio10.06 Quick Ratio10.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book0.37Miscellaneous Outstanding Shares52,981,000Free Float48,238,000Market Cap$11.42 million OptionableNot Optionable Beta0.51 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:ATBPF) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.